ECM
HAE icon

Everence Capital Management’s Haemonetics HAE Stock Holding History

Everence Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,650
Closed -$267K – 436
2018
Q1 		$267K Hold
3,650
– – 0.06% 328
2017
Q4 		$212K Buy
+3,650
New +$192K 0.05% 385

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Everence Capital Management's HAE Position: Q2 2018 in Review

Everence Capital Management sold out of Haemonetics (HAE) in Q2 2018, closing a stake of 3,650 shares — an estimated $267K sold.

Everence Capital Management first reported a position in HAE in Q4 2017 and held it in 2 quarters. The position peaked at $267K in Q1 2018. 293 funds tracked by Wall St. Rank hold HAE as of Q2 2018.

  • Everence Capital Management reported no remaining Haemonetics position as of Q2 2018 after selling out during the quarter.
  • Everence Capital Management sold 3,650 Haemonetics shares in Q2 2018, an estimated $267K.
  • Everence Capital Management first reported a position in Haemonetics in Q4 2017 and held it in 2 quarters.
  • Everence Capital Management's Haemonetics position peaked at $267K in Q1 2018.
  • 293 funds tracked by Wall St. Rank held Haemonetics as of Q2 2018.

Based on Everence Capital Management's 13F filing for Q2 2018, filed 26 Jul 2018.